U.S., June 2 -- ClinicalTrials.gov registry received information related to the study (NCT07619001) titled 'A Study to Evaluate the PK Similarity of AK104 in Healthy Chinese Male Participations' on May 26.
Brief Summary: This study is to evaluate the pharmacokinetic (PK) similarity of AK104 (an anti-PD-1/CTLA-4 bispecific antibody) from the proposed new manufacturing site and the approved original site in healthy male participants.
Study Start Date: June 01
Study Type: INTERVENTIONAL
Condition:
Healthy Male Adults Participants
Intervention:
DRUG: AK104 (New Site)
AK104 (New Site) 0.2mg/kg
DRUG: AK104 (Original Site)
AK104 (Original Site) 0.2mg/kg
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Akeso
Published by HT Digital Cont...